GlassScriptPhysician profile
Evan L Vogel
NPI 1235143066
$2,299.09
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $104 · 2021: $211 · 2022: $432 · 2023: $379 · 2024: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $587.85 | 2019-2024 | Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $348.77 | 2019-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $252.03 | 2019-2024 | Ingrezza |
| Abbvie INC. | $227.31 | 2021-2024 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $197.30 | 2021-2024 | Caplyta |
| Alkermes, INC. | $172.99 | 2019-2024 | Lybalvi |
| Janssen Pharmaceuticals, INC | $167.75 | 2019-2023 | Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $99.99 | 2019-2024 | Hetlioz, Fanapt |
| Sunovion Pharmaceuticals INC. | $81.64 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $41.07 | 2024 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $38.73 | 2022-2023 | Trintellix |
| Indivior INC. | $32.02 | 2024 | Perseris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.46 | 2023 | |
| Lundbeck LLC | $13.50 | 2022 | |
| Allergan, INC. | $11.47 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $10.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Vogel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.